Novel research illuminates breast milk’s unique contribution to COVID-19 defense in infants
Type: Press Releases
Topic(s): Conferences and Events
Real-world data on human milk-based fortification reveals limitations of protocol designs of two RCTs
Type: Press Releases
Topic(s): Company
Prolacta's human milk-based nutrition has touched the lives of 100,000 Premature and Critically Ill Infants Globally
Type: Press Releases
Topic(s): Company
Prolacta Bioscience recognizes advances in preterm care during NICU awareness month
Type: Press Releases
Topic(s): Company
Prolacta Bioscience applauds Ohio legislature for supporting Medicaid reimbursement for donor human milk-derived products
Type: Press Releases
Topic(s): Legislative
New study shows Prolacta’s human milk-based nutritional fortifiers save hospital NICUs up to $3.4M annually
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Clinical Studies on Prolact/Humavant CR Cost Savings / Cost Effectiveness Length of hospital stay Necrotizing Entercolitis (NEC)
Study reveals Prolacta’s 100% human milk-based nutritional fortifiers significantly increase bioactive proteins and antioxidant activity in human milk samples, outperforming cow milk-based fortifier
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Company Growth Probiotics Product
Prolacta Bioscience celebrates donor moms on World Human Milk Donation Day
Type: Press Releases
Topic(s): Company Donors
Prolacta Bioscience recognizes contributions of breast milk donors during National Nutrition Month
Type: Press Releases
Topic(s): Company Parents
Not finding the reference you’re looking for?
Use our main search field or email us at info@prolacta.com
